Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Yuna Katsuoka"'
Autor:
Kazuki Sakurai, Kei Saito, Shunsuke Hatta, Yuna Katsuoka, Kuniaki Meguro, Hisayuki Yokoyama, Toru Izumi
Publikováno v:
Clinical Case Reports, Vol 12, Iss 5, Pp n/a-n/a (2024)
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors.
Externí odkaz:
https://doaj.org/article/214ccb1defc349c3abfc7d42a37f1825
Autor:
Yurie Miyamoto‐Nagai, Naoya Mimura, Nobuhiro Tsukada, Nobuyuki Aotsuka, Masaki Ri, Yuna Katsuoka, Toshio Wakayama, Rikio Suzuki, Yoriko Harazaki, Morio Matsumoto, Kyoya Kumagai, Takaaki Miyake, Shuji Ozaki, Katsuhiro Shono, Hiroaki Tanaka, Arika Shimura, Yoshiaki Kuroda, Kazutaka Sunami, Kazuhito Suzuki, Takeshi Yamashita, Kazuyuki Shimizu, Hirokazu Murakami, Masahiro Abe, Chiaki Nakaseko, Emiko Sakaida
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 838-848 (2022)
Abstract Autologous stem cell transplantation (ASCT) remains an important therapeutic strategy for multiple myeloma; however, a proportion of patients fail to mobilize a sufficient number of peripheral blood stem cells (PBSCs) to proceed to ASCT. In
Externí odkaz:
https://doaj.org/article/1fbaa13893404ef3bdca3b5fe8e6800d
Autor:
Tohru Fujiwara, Takashi Ikeda, Yuki Nagasaka, Yoko Okitsu, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Naohisa Tomosugi, Hideo Harigae
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75568 (2013)
Hepcidin is the principal iron regulatory hormone, controlling the systemic absorption and remobilization of iron from intracellular stores. The expression of the hepcidin gene, HAMP, is increased in patients with anemia of chronic disease. Previousl
Externí odkaz:
https://doaj.org/article/613b6a17ea264977a9c7c2b9a129c01f
Autor:
Ken Ishiyama, Noriharu Nakagawa, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b739a6d580d7bb7f9e5237a9f936326c
https://doi.org/10.21203/rs.3.rs-2271688/v1
https://doi.org/10.21203/rs.3.rs-2271688/v1
Autor:
Kei Saito, Satoshi Ichikawa, Rina Ohtomo, Shunsuke Hatta, Yuna Katsuoka, Hideo Harigae, Tohru Izumi
Publikováno v:
Annals of Hematology. 101:2103-2105
Autor:
Sho Shibata, Yasuyuki Arai, Tadakazu Kondo, Shohei Mizuno, Kaito Harada, Shigesaburo Miyakoshi, Naoyuki Uchida, Yumiko Maruyama, Tetsuya Eto, Yuna Katsuoka, Kosei Matsue, Kaichi Nishiwaki, Satoru Takada, Noriko Doki, Mitsuru Itoh, Koji Nagafuji, Toshiro Kawakita, Junji Tanaka, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada
Publikováno v:
Transplantation and Cellular Therapy. 29:332.e1-332.e11
The alkylating agent busulfan is commonly used as conditioning in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML). However, a consensus has not yet been reached regarding the optimal busulfan dose in cord blood tra
Autor:
Makoto Onizuka, Hideki Nakasone, Tatsuo Ichinohe, Junya Kanda, Yoshiko Atsuta, Takafumi Kimura, Yoshinobu Kanda, Yuta Kawahara, Yuma Noguchi, Shuichi Ota, Satoko Morishima, Satoshi Takahashi, Takanori Ohta, Yukiyasu Ozawa, Hisayuki Yokoyama, Naoyuki Uchida, Yuna Katsuoka, Masatsugu Tanaka
Publikováno v:
Bone Marrow Transplantation. 56:1352-1363
Cytomegalovirus (CMV) reactivation in cord blood transplantation (CBT) may result in the proliferation and maturation of natural killer (NK) cells. Similarly, a mismatch of the killer cell immunoglobulin-like receptor (KIR)-ligand induces NK cell act
Autor:
Naoki Kobayashi, Shuichi Ota, Hideo Harigae, Hisayuki Yokoyama, Osamu Sasaki, Takahide Ara, Yasushi Onishi, Osamu Fukuhara, Koichiro Minauchi, Tomohumi Kimura, Joji Yamamoto, Toshihiro Ito, Shinji Nakajima, Yuna Katsuoka, Hideyoshi Noji
Publikováno v:
Annals of Hematology. 99:2351-2356
Lenalidomide (Len) and dexamethasone (dex) therapy is a standard therapy in patients with multiple myeloma. Elderly or unfit patients may reduce Len or dex doses to prevent toxicities that lead to treatment discontinuation. However, there have been f
Autor:
Hideyuki Nakazawa, Satoshi Yoshioka, Takanori Teshima, Tomonari Takemura, Yoshihiro Inamoto, Ritsuro Suzuki, Arata Ishii, Shinobu Tamura, Yuna Katsuoka, Takashi Tanaka, Koji Izutsu, Noriaki Kawano, Kazuto Togitani, Takahiro Fukuda, Toshiro Kawakita, Junichi Sugita, Junji Suzumiya, Makoto Onizuka, Ayumu Ito, Masafumi Fukaya, Kohei Higuchi, Ichiro Kawashima, Rika Sakai, Shin ichiro Fujiwara, Miho Nara, Tomomi Toubai, Yosuke Imai, Tadakazu Kondo, Hiroatsu Iida, Mika Nakamae, Sung-Won Kim, Ken-ichi Matsuoka, Seitaro Terakura
Publikováno v:
International Journal of Hematology. 112:674-689
We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before